Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups. The experimental group will receive 3 cycles of induction therapy with PD-1 antibody plus chemotherapy, followed by radiotherapy, and then maintenance therapy with PD-1 antibody monotherapy. The control group will receive concurrent chemoradiotherapy, followed by maintenance therapy with PD-1 antibody monotherapy. The primary endpoints are the complete response (CR) r

Trial Details

NCT ID
NCT07559045
Phase
PHASE2
Sponsor
Second Affiliated Hospital of Zunyi Medical University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy)
  • Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
Locations (sample)
  • Zunyi, Guizhou, China|27.68667,106.90722

Key Eligibility Criteria

  • Histologically or cytologically confirmed unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Adequate organ function (bone marrow, liver, renal, cardiac) within 2 weeks prior to randomization
  • Measurable or evaluable disease per RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →